Literature DB >> 24953743

Quality of life in Parkinson's disease patients with motor fluctuations and dyskinesias in five European countries.

Marlene C Hechtner1, Thomas Vogt2, York Zöllner3, Sabrina Schröder4, Julia B Sauer5, Harald Binder6, Susanne Singer7, Rafael Mikolajczyk8.   

Abstract

BACKGROUND: Little is known about the relationship between specific subtypes of treatment-associated motor complications and different domains of health-related Quality of Life (QoL) in patients with Parkinson's disease (PD). Larger studies that investigate these aspects within a cross-cultural setting are scarce.
OBJECTIVE: To assess QoL and its association with on-off fluctuations, peak-dose dyskinesias, biphasic dyskinesias, and off-dystonias in PD patients from five European countries.
METHODS: Data from 817 PD patients were collected cross-sectionally in France, Germany, Italy, Spain, and the UK. QoL was measured with the generic EuroQoL 5-Dimension questionnaire (EQ-5D) and the disease-specific Parkinson's Disease Questionnaire-39 (PDQ-39). Multivariable linear regression analyses were performed to test the associations of motor complication subtypes with QoL.
RESULTS: Thirty-three percent of the patients (varying from 23% in Italy to 58% in France) suffered from motor complications, either a single subtype or a combination of different subtypes. On-off fluctuations were associated with a 7.1 percentage point decrease in the EQ-5D (p < 0.001) and a 3.6 percentage point deterioration in the PDQ-39 (p = 0.01). Dyskinesias were not seen to affect global QoL scores, but had detrimental effects on the PDQ-39 dimensions activities of daily living, cognitions, stigma, and bodily discomfort. Patients from Spain, Italy, and France had lower global QoL scores in the multivariable analyses than patients from Germany and the UK.
CONCLUSION: Motor complications, primarily on-off fluctuations, may impact QoL in PD patients. This substantiates the importance of clinical strategies targeting the prevention, delay of onset, and management of motor complications in PD patients.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Dyskinesia; Europe; Motor complications; Motor fluctuations; Parkinson's disease; Quality of life

Mesh:

Substances:

Year:  2014        PMID: 24953743     DOI: 10.1016/j.parkreldis.2014.06.001

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  51 in total

1.  Effectiveness and safety of opicapone in Parkinson's disease patients with motor fluctuations: the OPTIPARK open-label study.

Authors:  Heinz Reichmann; Andrew Lees; José-Francisco Rocha; Diogo Magalhães; Patrício Soares-da-Silva
Journal:  Transl Neurodegener       Date:  2020-03-04       Impact factor: 8.014

2.  Poor nighttime sleep is positively associated with dyskinesia in Parkinson's disease patients.

Authors:  Cheng-Jie Mao; Ya-Ping Yang; Ju-Ping Chen; Fen Wang; Jing Chen; Jin-Ru Zhang; Hui-Jun Zhang; Sheng Zhuang; Yi-Tong Xiong; Chen-Chen Gu; Wen Yuan; Juan-Ying Huang; Alexander Fay; Chong-Ke Zhong; Chun-Feng Liu
Journal:  Parkinsonism Relat Disord       Date:  2017-12-21       Impact factor: 4.891

3.  ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study): A Randomized Clinical Trial.

Authors:  Rajesh Pahwa; Caroline M Tanner; Robert A Hauser; Stuart H Isaacson; Paul A Nausieda; Daniel D Truong; Pinky Agarwal; Keith L Hull; Kelly E Lyons; Reed Johnson; Mary Jean Stempien
Journal:  JAMA Neurol       Date:  2017-08-01       Impact factor: 18.302

4.  Assessment of plasma creatine kinase as biomarker for levodopa-induced dyskinesia in Parkinson's disease.

Authors:  Anna Delamarre; François Tison; Qin Li; Monique Galitzky; Olivier Rascol; Erwan Bezard; Wassilios G Meissner
Journal:  J Neural Transm (Vienna)       Date:  2019-05-16       Impact factor: 3.575

5.  Metabolic Profile in Plasma AND CSF of LEVODOPA-induced Dyskinesia in Parkinson's Disease: Focus on Neuroinflammation.

Authors:  Bruno L Santos-Lobato; Luiz Gustavo Gardinassi; Mariza Bortolanza; Ana Paula Ferranti Peti; Ângela V Pimentel; Lúcia Helena Faccioli; Elaine A Del-Bel; Vitor Tumas
Journal:  Mol Neurobiol       Date:  2021-12-02       Impact factor: 5.590

6.  The Parkinson's Disease Activities of Daily Living, Interference, and Dependence Instrument.

Authors:  Linda S Deal; Emuella Flood; Daniela E Myers; Jacob Devine; David L Gray
Journal:  Mov Disord Clin Pract       Date:  2019-09-06

Review 7.  Understanding, Impact, and Communication of "Off" Periods in Parkinson's Disease: A Scoping Review.

Authors:  Tara Rastgardani; Melissa J Armstrong; Anna R Gagliardi; Connie Marras
Journal:  Mov Disord Clin Pract       Date:  2018-10-09

8.  Oral Levodopa Formulation Does Not Affect Progression of Parkinson Disease.

Authors:  Ambica Sethi; Sonam Dilwali; Morgan McCreary; Richard B Dewey
Journal:  Clin Neuropharmacol       Date:  2021 Mar-Apr 01       Impact factor: 1.592

9.  Suicide in Parkinson's Disease.

Authors:  Wei Li; Masoom M Abbas; Sanchalika Acharyya; Hwee Lan Ng; Kay Yaw Tay; Wing Lok Au; Louis C S Tan
Journal:  Mov Disord Clin Pract       Date:  2018-03-02

10.  Patient Utilities in Health States Based on Hoehn and Yahr and Off-Time in Parkinson's Disease: A Swedish Register-Based Study in 1823 Observations.

Authors:  Jenny M Norlin; Klas Kellerborg; Per Odin
Journal:  Pharmacoeconomics       Date:  2021-07-07       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.